Loading…
NCNA
NuCana plc
NASDAQ· Healthcare· Biotechnology· CUSIP 67022C304
$1.33+0.76%Price as of Sep 22, 22:38 UTC · updated once a day, after the close
Key metrics
- Market cap
- $5.54M
- P/E
- 0.0x
- Forward P/E
- —
- P/B
- 0.2x
- Dividend yield
- —
- Payout
- —
- EPS
- $66.94
- ROE
- -70.26%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.24
- 52-week high
- $7.22
- 52-week low
- $1.21
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.10▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.60 | $238.00 | $1,480.00 | $3,300.00 | |
| P/B | 4825.7x | 3079.5x | 5657.7x | 5205.4x | 4446.0x |
| EPS | $0.00 | -$1,300.00 | -$2,650.00 | -$3,050.00 | |
| ROE | -153.14% | -120.66% | -319.06% | -185.61% | -83.17% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PMCBPharmaCyte Biotech, Inc. | $0.52 | — | 0.2x | — | -44.72% | $5.53M |
| PULMPulmatrix, Inc. | $1.51 | — | 3.5x | — | -98.35% | $5.51M |
| JUNSJupiter Neurosciences Inc | $4.18 | — | — | — | -1888.70% | $5.51M |
| CVKDCadrenal Therapeutics, Inc. | $1.54 |
About the company
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
- 10
- Edinburgh, United Kingdom
Company description provided by Yahoo Finance.